Replies to post #226022 on Biotech Values

[bmazeraski]

Maybe this data is really, really good. :-)

From an Aug 12 press release:

Second Quarter Highlights and Recent Developments

Remained on schedule to report top line data in Q3 2019 for AR-105's global Phase 2 clinical trial for the treatment of ventilator-associated pneumonia (VAP) caused by Pseudomonas aeruginosa (P. aeruginosa).